Inhibition of herpes simplex virus type 1 with the modified green tea polyphenol palmitoyl-epigallocatechin gallate

Food and Chemical Toxicology

Volumn 52, Issue , 2013, Pages 207-215

  De Oliveira, Aline ^a   Adams, Sandra D ^b   Lee, Lee H ^b   Murray, Sean R ^c   Hsu, Stephen D ^d   Hammond, Jeffrey R ^c   Dickinson, Douglas ^d   Chen, Ping ^e   Chu, Tin Chun ^a  

^a SETON HALL UNIVERSITY   (United States)

^b MONTCLAIR STATE UNIVERSITY   (United States)

^c CALIFORNIA STATE UNIVERSITY   (United States)

^d MEDICAL COLLEGE OF GEORGIA   (United States)

^e ZHEJIANG UNIVERSITY   (China)

Author keywords

DAPI; EGCG; GFP; HSV; HSV 1; HSV 2; P EGCG; Palmitoyl EGCG; Vero cells

Indexed keywords

ANTIVIRUS AGENT; EPIGALLOCATECHIN GALLATE;

ANIMAL CELL; ARTICLE; BINDING ASSAY; CELL CULTURE; CELL PROLIFERATION; CELL VIABILITY; DRUG POTENCY; FLUORESCENCE MICROSCOPY; HERPES SIMPLEX; HERPES SIMPLEX VIRUS 1; NONHUMAN; PLAQUE FORMING CELL; POLYMERASE CHAIN REACTION; REAL TIME POLYMERASE CHAIN REACTION; TEA; VERO CELL; VIRUS ATTACHMENT; VIRUS PARTICLE;

ANIMALS; ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CATECHIN; CELL PROLIFERATION; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION REGULATION, VIRAL; GREEN FLUORESCENT PROTEINS; HERPES SIMPLEX; HERPESVIRUS 1, HUMAN; MICROSCOPY, FLUORESCENCE; TEA; VERO CELLS; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS;

HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 2; SIMPLEXVIRUS;

EID: 84871547918     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2012.11.006     Document Type: Article

References (45)

1. Akhtar J., Shukla D. Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry. FEBS J. 2009, 276(24):7228-7236.
2. Akkarawongsa R., Pocaro N.E., et al. Multiple peptides homologous to herpes simplex virus type 1 glycoprotein B inhibit viral infection. Antimicrob. Agents Chemother. 2009, 53(3):987-996.
3. Babich H., Krupka M.E., et al. Differential in vitro cytotoxicity of (-)-epicatechin gallate (ECG) to cancer and normal cells from the human oral cavity. Toxicol. In Vitro 2005, 19(2):231-242.
4. Belshe R.B., Leone P.A., et al. Efficacy results of a trial of a herpes simplex vaccine. N. Engl. J. Med. 2012, 366(1):34-43.
5. Bernstein D.I., Stanberry L.R. Herpes simplex virus vaccines. Vaccine 1999, 17(13-14):1681-1689.
6. Brady R.C., Bernstein D.I. Treatment of herpes simplex virus infections. Antiviral Res. 2004, 61(2):73-81.
7. Carfi A., Willis S.H., et al. Herpes simplex virus glycoprotein D bound to the human receptor HveA. Mol. Cell 2001, 8(1):169-179.
8. Chen P., Dickinson D., et al. Lipid-soluble green tea polyphenols: stabilized for effective formulation. Handbook of Green Tea & Health Research 2009, 500. Nova Science Publishers, Lancaster. H. McKinley, M. Jamieson (Eds.).
9. Chen P., Tan Y., et al. A novel long-chain acyl-derivative of epigallocatechin-3-O-gallate prepared and purified from green tea polyphenols. J. Zhejiang Univ. Sci. 2003, 4(6):714-718.
10. Ciesek S., von Hahn T., et al. The green tea polyphenol epigallocatechin-3-gallate (EGCG) inhibits hepatitis C virus (HCV) entry. Hepatology 2011, 54(6):1947-1955.
11. Fatahzadeh M., Schwartz R.A. Human herpes simplex virus infections: epidemiology, pathogenesis, symptomatology, diagnosis, and management. J. Am. Acad. Dermatol. 2007, 57(5):737-763. (quiz 64-6).
12. Foster T.P., Rybachuk G.V., et al. Expression of the enhanced green fluorescent protein by herpes simplex virus type 1 (HSV-1) as an in vitro or in vivo marker for virus entry and replication. J. Virol. Methods 1998, 75(2):151-160.
13. Frobert E., Cortay J.C., et al. Genotypic detection of acyclovir-resistant HSV-1: characterization of 67 ACV-sensitive and 14 ACV-resistant viruses. Antiviral Res. 2008, 79(1):28-36.
14. Garner J.A. Herpes simplex virion entry into and intracellular transport within mammalian cells. Adv. Drug Deliv. Rev. 2003, 55(11):1497-1513.
15. Hauber I., Hohenberg H., et al. The main green tea polyphenol epigallocatechin-3-gallate counteracts semen-mediated enhancement of HIV infection. Proc. Natl. Acad. Sci. U.S.A. 2009, 106(22):9033-9038.
16. He W., Li L.X., et al. Epigallocatechin gallate inhibits HBV DNA synthesis in a viral replication-inducible cell line. World J. Gastroenterol. 2011, 17(11):1507-1514.
17. Ho H.Y., Cheng M.L., et al. Antiviral effect of epigallocatechin gallate on enterovirus 71. J. Agric. Food Chem. 2009, 57(14):6140-6147.
18. Isaacs C.E., Wen G.Y., et al. Epigallocatechin gallate inactivates clinical isolates of herpes simplex virus. Antimicrob. Agents Chemother. 2008, 52(3):962-970.
19. Kanaka S., Kim M., et al. Antibacterial substances in Japanese green tea extract against streptococcus mutans, a cariogenic bacterium. Agric. Biol. Chem. 1989, 53:2307-2311.
20. Koyama A.H., Adachi A. Induction of apoptosis by herpes simplex virus type 1. J. Gen. Virol. 1997, 78(Pt 11):2909-2912.
21. Lambert J.D., Kim D.H., et al. Transdermal delivery of (-)-epigallocatechin-3-gallate, a green tea polyphenol, in mice. J. Pharm. Pharmacol. 2006, 58(5):599-604.
22. Lebel A., Boivin G. Pathogenicity and response to topical antiviral therapy in a murine model of acyclovir-sensitive and acyclovir-resistant herpes simplex viruses isolated from the same patient. J. Clin. Virol. 2006, 37(1):34-37.
23. Morfin F., Thouvenot D. Herpes simplex virus resistance to antiviral drugs. J. Clin. Virol. 2003, 26(1):29-37.
24. Mori S., Miyake S., et al. Enhanced anti-influenza A virus activity of (-)-epigallocatechin-3-O-gallate fatty acid monoester derivatives: effect of alkyl chain length. Bioorg. Med. Chem. Lett. 2008, 18(14):4249-4252.
25. Paterson I., Anderson E.A. Chemistry. The renaissance of natural products as drug candidates. Science 2005, 310(5747):451-453.
26. Piret J., Boivin G. Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management. Antimicrob. Agents Chemother. 2011, 55(2):459-472.
27. Sang S., Lee M.J., et al. Stability of tea polyphenol (-)-epigallocatechin-3-gallate and formation of dimers and epimers under common experimental conditions. J. Agric. Food Chem. 2005, 53(24):9478-9484.
28. Sharangi A.B. Medicinal and therapeutic potentialities of tea (Camellia sinensis L.) - a review. Food Res. Int. 2009, 42(5-6):529-535.
29. Shukla D., Spear P.G. Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. J. Clin. Invest. 2001, 108(4):503-510.
30. Song J.M., Lee K.H., et al. Antiviral effect of catechins in green tea on influenza virus. Antiviral Res. 2005, 68(2):66-74.
31. Spear P.G., Manoj S., et al. Different receptors binding to distinct interfaces on herpes simplex virus gD can trigger events leading to cell fusion and viral entry. Virology 2006, 344(1):17-24.
32. Stanberry L.R. Understanding Herpes 2006, University Press of Mississippi, Jackson. second Revised.
33. Stanberry L.R., Cunningham A.L., et al. Prospects for control of herpes simplex virus disease through immunization. Clin. Infect. Dis. 2000, 30(3):549-566.
34. Sueoka N., Suganuma M., et al. A new function of green tea: prevention of lifestyle-related diseases. Ann. N. Y. Acad. Sci. 2001, 928:274-280.
35. Toka F.N., Suvas S., et al. CD4+ CD25+ T cells regulate vaccine-generated primary and memory CD8+ T-cell responses against herpes simplex virus type 1. J. Virol. 2004, 78(23):13082-13089.
36. Van de Perre P., Segondy M., et al. Herpes simplex virus and HIV-1: deciphering viral synergy. Lancet Infect. Dis. 2008, 8(8):490-497.
37. Wald A., Link K. Risk of human immunodeficiency virus infection in herpes simplex virus type 2-seropositive persons: a meta-analysis. J. Infect. Dis. 2002, 185(1):45-52.
38. Wang L., Liu L., et al. Egress of HSV-1 capsid requires the interaction of VP26 and a cellular tetraspanin membrane protein. Virol. J. 2010, 7:156.
39. Weisburg J.H., Weissman D.B., et al. In vitro cytotoxicity of epigallocatechin gallate and tea extracts to cancerous and normal cells from the human oral cavity. Basic Clin. Pharmacol. Toxicol. 2004, 95(4):191-200.
40. Willard M. Rapid directional translocations in virus replication. J. Virol. 2002, 76(10):5220-5232.
41. Williamson M.P., McCormick T.G., et al. Epigallocatechin gallate, the main polyphenol in green tea, binds to the T-cell receptor, CD4: potential for HIV-1 therapy. J. Allergy Clin. Immunol. 2006, 118(6):1369-1374.
42. Xu F., Sternberg M.R., et al. Trends in herpes simplex virus type 1 and type 2 seroprevalence in the United States. JAMA 2006, 296(8):964-973.
43. Yamaguchi K., Honda M., et al. Inhibitory effects of (-)-epigallocatechin gallate on the life cycle of human immunodeficiency virus type 1 (HIV-1). Antiviral Res. 2002, 53(1):19-34.
44. Zhao M., Jiang J., et al. A proprietary topical preparation containing EGCG-stearate and glycerin with inhibitory effects on herpes simplex virus: case study. Inflammation Allergy Drug Targets 2012, 11(5):364-368.
45. Zhu Q.Y., Zhang A., et al. Stability of green tea catechins. J. Agric. Food Chem. 1997, 45(12):4624-4628.